Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view). Triangles mark past earnings reports, colored by that day’s move; ticks mark ex-dividend dates — hover either for the date. Volume is the shaded bars under the price; switch on RSI or MACD above for a full-history oscillator panel, not just today’s reading.
Reader sentiment, not investment advice. One vote per visitor; click again to change it.
LKFT is priced at $29.51 right now, up 0.48% on the session. That puts its market value at $1.93B, 2805th largest among the 3132 stocks we cover.
The 52-week range is $25.68 to $36.24. Today's price is about 36% of the way from the low to the high. Holders are behind 17.0% over twelve months, and down 3.5% across the last three months.
Price is above the 50-day average ($28.34) but below the 200-day ($30.13); RSI is 54, and the last 30 sessions moved at roughly 33% annualized volatility.
Buyers are paying 2.9 times trailing earnings. The median for its industry group is 21.2.
2 analysts follow the stock and the average call is "buy". The mean target, $37.50, sits 27.1% over where the stock trades.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
Composite of 3 factors below, ranked against the 3132 U.S. stocks BeStock covers.
Cheaper on P/E than most of BeStock’s coverage scores higher.
Trading closer to its 52-week high than most peers scores higher.
2 analysts, consensus Buy.
How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.
LKFT is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.
Since 2021-01-04, the strategy has returned 389% (231.1% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated weekly — not a guarantee of future results, and not a BeStock recommendation.
What Wall Street analysts and Morningstar's fair-value model expect for the stock
Wall Street’s average 12-month target is $37.50, 27.1% above today’s price, with a consensus rating of Buy. Morningstar’s fair value model puts the stock at $39.09, so shares trade 24.5% below that estimate.
Figures are Wall Street analyst consensus and Morningstar’s independent fair-value model, sourced as noted above.
Price return over each window, from adjusted daily and weekly closes
| Indicator | Value | Signal |
|---|---|---|
| Price vs 20-day average | +2.6% | Bullish |
| Price vs 50-day average | +4.1% | Bullish |
| Price vs 200-day average | -2.1% | Bearish |
| 50-day vs 200-day | 50d below 200d | Bearish |
| RSI (14) | 54.1 | Bullish |
| MACD (12,26,9) | 0.33 | Bullish |
| Bollinger band position | 65% | Bullish |
Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.
Quote as of Oct 5, 2026 10:20 pm ET. Prices can lag the live tape. This is background information, not a recommendation.
Ranks are among the 3,132 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.
Set against the peer table: at 2.9x earnings, LKFT looks cheap against the market, and trades 86% below the 21.2x median among Biotechnology names. The two comparisons do not always agree.
$29.51 is the latest print for LKFT, a move of +0.48% against yesterday's close of $29.37. Today's low and high so far: $29.24 and $29.91.
Equity value comes to $1.93B at the current price. By that measure it is number 2805 of the 3132 names in our coverage.
Buyers pay 2.9 times the last twelve months of profit (EPS $5.47).
The year's floor is $25.68 and the ceiling $36.24. Shares are 18.6% away from that ceiling.
Our data shows no dividend paid by Lakefront Biotherapeutics over the trailing twelve months.
Of 2 analysts, 50% say buy, 50% hold and 0% sell. Price targets average $37.50, with the most cautious at $30.00 and the most optimistic at $45.00.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.
No comments yet — be the first to weigh in on LKFT.